Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis
| Autor: | Jasmohan S. Bajaj, Bradley Reuter, Chathur Acharya, Hamzeh Saraireh, Andrew Fagan, Nikki Duong, Ramzi Hassouneh, Omar Nadhem |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Cirrhosis Gastroenterology Article Rifaximin 03 medical and health sciences chemistry.chemical_compound Lactulose 0302 clinical medicine Cognition Gastrointestinal Agents Internal medicine medicine Humans Effects of sleep deprivation on cognitive performance Adverse effect Hepatic encephalopathy Hepatology business.industry medicine.disease chemistry 030220 oncology & carcinogenesis Hepatic Encephalopathy Defecation 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Clin Gastroenterol Hepatol |
| ISSN: | 1542-7714 |
| Popis: | The spectrum of hepatic encephalopathy (HE) ranges from overt HE (OHE) to cognitive impairment (ie, covert) HE (CHE).1 The first-line therapy is lactulose, which is titrated to achieve ~2-3 soft/loose daily bowel movements (BM). This metric is considered dogma for practitioners despite erratic results, GI adverse events, and poor tolerance in Western countries.1 There are logistic barriers for the widespread uptake of rifaximin, the second-line therapy. Moreover, although BM frequency-directed dose titration of lactulose is the usual practice, its impact on objective cognitive performance is unclear. Our aim is to determine the impact of BM frequency on cognition in patients with/without prior OHE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|